Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study.

Shuang XiaHui GongYi-Chang ZhaoLin GuoYikun WangBikui ZhangMayur SarangdharYoshihiro Noguchi Miao Yan

Published in: Cancers (2022)

Our study suggested ICIs, especially nivolumab and atezolizumab, tended to increase the risk of pulmonary sepsis more than other anticancer regimens. Clinicians should be vigilant in the prevention and management of pulmonary sepsis during ICIs therapy.

Keyphrases

pulmonary hypertension
acute kidney injury
intensive care unit
septic shock
emergency department
palliative care
cell therapy